Sulbutiamine for Health & Longevity
Evidence Review created on 09/25/2026 using AI4L + evidence-mcp / Grok 4
Also known as: Arcalion, Enerion, Bisibutiamine, isobutyrylthiamine disulfide, Sulbuthiamine
Motivation
Sulbutiamine (a made form of vitamin B1) was built to dissolve in fat and reach the brain more easily than ordinary vitamin B1. It is a medicine for low drive and tiredness in several countries, and it is also sold as a supplement. People focused on long-term health have looked at it because low energy, mental stamina, and brain aging are daily concerns.
It began as a Japanese effort against severe vitamin B1 deficiency, then became a French medicine for tiredness that has no single disease cause. Later animal work suggested effects on memory-related brain chemicals. Human studies have looked at tiredness, slowing during low mood, and early memory disease. Those results do not line up. Some reports without a comparison group look favorable, and the main placebo comparison in tiredness after infection did not show a benefit that lasted through the full course.
This review examines what sulbutiamine is, how it acts, which benefits and harms the studies actually support, and how it has been dosed, stopped, and monitored. The focus is the evidence relevant to long-term health in proactive adults, not a guideline for the general population.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Overviews that discuss sulbutiamine itself, including asthenic states (tiredness without one disease cause), outside the systematic-review literature.
-
Role of the Synthetic B1 Vitamin Sulbutiamine on Health - Starling-Soares et al., 2020
A narrative review of history, brain vitamin B1 metabolism, fatigue and memory studies, and side effects. It is the broadest single overview, and it stresses how few controlled trials exist.
-
Pharmacologic and therapeutic features of sulbutiamine - Van Reeth, 1999
An earlier clinical review of sulbutiamine as an anti-tiredness medicine, covering animal work and the forms of human fatigue then under study.
-
On the specific treatment of asthenic states: focus on sulbutiamine - Bykov & Bekker, 2022
A narrative review of Enerion absorption, anti-tiredness mechanisms, and comparisons with other agents. The authors judge that evidence favorably.
Fewer than five sources met the bar for a high-level overview that is not a systematic review. No relevant overview was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, or Lifespan.io. The list is not padded with passing mentions.
Grokipedia
Grokipedia’s dedicated page summarizes sulbutiamine as a synthetic fat-soluble vitamin B1 derivative, including its chemistry and related compounds. It is a tertiary overview, not a trial report.
Examine
Sulbutiamine benefits, dosage, and side effects
Examine treats sulbutiamine as a synthetic vitamin B1 dimer with limited human evidence, mainly for infection-related fatigue, and notes that trials have used 400 mg daily without a settled schedule.
ConsumerLab
No ConsumerLab article on sulbutiamine was found. Where it is sold as a supplement, ConsumerLab has not published a dedicated review. Where it is a prescription medicine, ConsumerLab does not typically review prescription medicines.
Systematic Reviews
No systematic reviews or meta-analyses for Sulbutiamine were found on PubMed as of September 25, 2026.
Mechanism of Action
Sulbutiamine is a synthetic dimer of two vitamin B1 molecules joined by a disulfide (a sulfur bond), with an isobutyryl ester (a fat-soluble tag) on each half. It crosses the blood-brain barrier (the filter between blood and brain) more readily than vitamin B1 itself. Inside cells the disulfide is reduced and the esters are cleaved, releasing thiamine (vitamin B1). Thiamine pyrophosphokinase (the enzyme that activates vitamin B1) then makes thiamine diphosphate, the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase (enzymes that process carbohydrate). A smaller pool of that cofactor feeds thiamine triphosphate, a membrane-associated form. In rats, sulbutiamine raises tissue thiamine triphosphate (Bettendorff et al.).
It is not a selective receptor drug. Chronic exposure in rodents increases dopamine D1 receptor density (a dopamine docking site tied to drive) in the prefrontal cortex (the front of the brain’s outer layer) and lowers some kainate binding (a glutamate receptor type) (Trovero et al.). Choline uptake in the hippocampus (a memory area), a step toward acetylcholine (the memory signal), rose about 10% in mice (Micheau et al.).
Oral absorption is rapid. The Arcalion product summary states a peak blood level at 1–2 hours, an elimination half-life of about 5 hours, and urinary excretion. Clearance is reduction and ester cleavage to thiamine, not cytochrome P450 (the liver enzyme system that clears many drugs). Animal work shows brain entry that benfotiamine, a different vitamin B1 derivative, does not match: oral benfotiamine raised mouse blood and liver thiamine but not brain thiamine (Volvert et al.).
Historical Context & Evolution
Sulbutiamine was synthesized in Japan in the mid-1960s, as an isobutyryl thiamine disulfide, among fat-soluble vitamin B1 derivatives aimed at beriberi (the disease of severe vitamin B1 deficiency). The design goal was a form that entered cells, and the brain, faster than water-soluble vitamin B1.
In the 1970s the French company Servier marketed it as Arcalion for asthenia (tiredness and low drive without one disease explanation). That shift, from deficiency treatment to symptomatic fatigue, is why it later drew interest beyond beriberi. Clinical work then used rating scales of inhibition (slowed drive and movement) and fatigue rather than deficiency outcomes.
From the 1980s, rodent studies reported better long-term memory and higher hippocampal cholinergic activity (acetylcholine-related signaling), which moved the compound into nootropic discussion (interest in compounds hoped to aid thinking). Human trials followed in tiredness after infection, slowing during depression, early Alzheimer disease, diabetic nerve injury, and later fatigue in multiple sclerosis (a disease in which immune attack damages nerve insulation). Results were mixed. Some open series looked favorable, and the largest placebo-controlled fatigue trial did not show a lasting effect at one month. Sports-doping laboratories later found it in in-competition urine, which shows that athletes were using it, not that performance improved.
No lifespan experiment adopted it. Interest for health optimization rests on brain delivery of vitamin B1 and on the fatigue literature, both narrower than the marketing history. What changed over time is the target, from deficiency to symptoms, not a settled verdict that the symptoms respond.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: human clinical endpoints come from single trials or uncontrolled series, not from more than one trial of the same outcome.
Medium 🟩 🟩
Slowing during depression
In one multicenter randomized trial, adults in a major depressive episode received clomipramine (a medicine that raises serotonin and norepinephrine signaling) plus sulbutiamine or placebo (Lôo et al.). Depression severity improved similarly in both groups. Disability and self-rated emotional, cognitive, and behavioral performance improved more with sulbutiamine by four weeks. The trial did not show an antidepressant effect.
Magnitude: Functional and self-rated performance scores improved versus placebo by four weeks, while depression scores did not; the report gives no point difference on those scales.
Memory
One randomized trial tested sulbutiamine with donepezil (a medicine that slows breakdown of acetylcholine) in early and moderate Alzheimer disease (Ollat et al.). Episodic memory and daily activities improved only when sulbutiamine came before donepezil, and fell when donepezil was followed by placebo, while attention improved in both sequences. Healthy adults have not been tested; mice showed better long-term memory and about 10% higher hippocampal choline uptake (Micheau et al.). This is one drug-sequence trial plus animal work, not sulbutiamine alone against placebo.
Magnitude: Episodic memory and daily activities moved favorably only in the sulbutiamine-then-donepezil sequence, versus a decline in episodic memory when donepezil was followed by placebo; the report gives no score change.
Childhood bedwetting ⭕️ Not Central to Health & Longevity
One randomized trial in children compared sulbutiamine with imipramine (an older antidepressant also used for bedwetting), not with placebo (Ahmed Mahmoud et al.). Complete dryness was more common, and relapse less common, on sulbutiamine, with fewer adverse events than imipramine. This bears on childhood bladder control during sleep, not on adult healthspan.
Magnitude: Complete response at six months was 52.7% with sulbutiamine alone versus 37.3% with imipramine; relapse was 28.7% versus 43.6%.
Diabetic nerve conduction
An open randomized comparison in type 2 diabetes found better nerve conduction after six weeks of sulbutiamine than with no added treatment (Kiew et al.). Symptom scores did not differ between groups. It is one small, unblinded study.
Magnitude: Nerve conduction and the muscle electrical response improved versus no treatment, while symptom scores did not differ between groups; the report gives no meters-per-second figure.
Low 🟩
Fatigue and asthenia ⚠️ Conflicted
Sulbutiamine matched placebo at day 28 after a day-7 dip on 600 mg (Tiev 1999). Open series look better: a commercial infection add-on, multiple sclerosis, and sulbutiamine versus piracetam (a memory medicine) after injury (Shah 2003; Sevim 2017; Levin & Slizkova). Net reading: a lasting benefit is not established.
Magnitude: In the placebo-controlled trial, fatigue scores did not differ at day 28. In the open multiple-sclerosis series, the fatigue score fell from 77 to 60.5 at day 60. The controlled day-28 result showed no difference.
Psychogenic erectile function ⭕️ Not Central to Health & Longevity
An uncontrolled series in psychogenic erectile dysfunction (erection difficulty with a psychological origin) reported higher erectile-function scores after 30 days of Enerion (Dmitriev et al.). This bears on sexual function, not on longevity. There was no placebo group.
Magnitude: The erectile-function score rose from 17.5 to 24.8, and 16 of 20 men improved, with no placebo comparison.
Speculative 🟨
Protection of brain cells
Protection against low oxygen is reported in rat nerve cells (Kwag et al.). No human trial has measured stroke outcome or aging rate. The basis is laboratory work only.
Athletic performance
About 100 of 16,000 doping-control samples in one laboratory contained sulbutiamine, mostly in competition (Sobolevsky & Rodchenkov). That shows use, not faster performance. No controlled trial exists; the basis is anecdotal only.
Diabetic kidney injury
Sulbutiamine lowered blood sugar and kidney-injury markers in rats with chemically induced diabetic kidney disease (Ghaiad et al.). No human trial has measured kidney outcomes. The basis is animal work only.
Tumor-cell growth
In tumor cells, sulbutiamine slowed growth more than vitamin B1 alone (Jonus et al.). In mice, sulbutiamine did not shrink an implanted tumor, while benfotiamine did. The basis is laboratory work only.
Parasite enzyme block
Sulbutiamine inactivated an enzyme of the gut parasite Encephalitozoon intestinalis in a test tube (García-Torres et al.). No human infection trial exists. The basis is laboratory work only.
Benefit-Modifying Factors
-
Baseline vitamin B1 status: A low store of thiamine diphosphate is the setting where a prodrug (a compound the body turns into vitamin B1) has a cofactor rationale. Trials did not split results by that level.
-
Sex: In the post-infectious fatigue trial, only women on 600 mg looked better at day 7, and that gap was gone by day 28. No sex-specific benefit is established.
-
Age: Adult trials used clinical groups, not healthy older adults. The bedwetting trial was in children at a lower dose and does not define an older-adult response.
-
Existing illness: Studied settings are infection-related fatigue, multiple sclerosis, depression, early Alzheimer disease, diabetic nerve injury, and psychogenic erectile dysfunction. Healthy-adult use is untested.
-
Genetic variants: No sulbutiamine response by vitamin B1 transporter or enzyme variant is published. Dose is not adjusted for a named gene.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: human adverse-event findings are single trials, open series, a product label, or one case, not the same adverse endpoint in more than one trial.
Medium 🟥 🟥
No risk reaches Medium: the controlled fatigue trial found similar complaints on sulbutiamine and placebo, and other human reports are open series or a single case, not one consistent adverse endpoint in a controlled trial.
Low 🟥
Mild adverse events ⚠️ Conflicted
Uncommon label effects, about 1–10 per 1,000, are agitation, headache, tremor, nausea, vomiting, malaise, and rash. Stomach pain, diarrhea, and insomnia are also reported (Arcalion summary; Starling-Soares et al.). A placebo trial had similar complaints. Net reading: a rate above placebo is not established.
Magnitude: An open series recorded side effects in 10 of 1,772 people (0.6%). In a randomized trial, 3 of 40 people on sulbutiamine alone had headache or insomnia (8%). The placebo-controlled trial counted 15 people with side effects on sulbutiamine and 12 on placebo.
Overdose agitation
The product summary states that massive intake can cause transient agitation, euphoria, and tremor of the extremities, and that these pass (product summary). Published trials have not measured an overdose rate (Starling-Soares et al.).
Magnitude: After massive intake, transient agitation, euphoria, and limb tremor are described; the label gives no rate or dose threshold.
Disrupted care in bipolar disorder
One case described an adult with bipolar disorder (a condition of severe mood and energy swings) who took rising amounts of over-the-counter sulbutiamine and missed psychiatric visits (Douzenis et al.). A depression trial did not show mania or suicide attempts on sulbutiamine (Lôo et al.).
Magnitude: Not quantified in available studies. Only a single case describes escalating use, so no rate of misuse or mood switch is known.
Manic episode ⚠️ Conflicted
Case reports outside PubMed describe a manic episode (elevated mood and energy with little sleep) after sulbutiamine, including at a usual dose. A depression trial did not show mania (Lôo et al.). Net reading: a rate of mania is not established.
Magnitude: Not quantified in available studies. Only case reports describe the episode, so no rate is known.
Speculative 🟨
Sleep change at extreme doses
High doses changed sleep and caused drooling in monkeys at about 300 mg per kg (Starling-Soares et al.). Usual-dose trials have not shown that extreme pattern. The basis is animal work only.
Risk-Modifying Factors
-
Genetic variants: No transporter or vitamin B1-enzyme variant is known to raise sulbutiamine adverse events. The label does not use a gene test to set dose.
-
Baseline state: People who already have agitation or insomnia have less room before labeled nervous-system effects matter. Trials did not stratify harm by a baseline biomarker.
-
Sex: The placebo-controlled fatigue trial did not report adverse events separately for women and men. No sex-specific harm is established.
-
Existing illness: Bipolar disorder is the setting of the one misuse case. Pregnancy data are limited, and breastfeeding is a labeled avoidance. Multiple sclerosis and diabetes series reported no serious events, but they were small.
-
Age: The label says safety under 18 years is not established. In the bedwetting trial, adverse events were less frequent on sulbutiamine than on imipramine. Separate risk figures for older adults are not published.
Key Interactions & Contraindications
-
Diuretics (medicines that increase urine, such as furosemide and hydrochlorothiazide): Severity: monitor. They can increase urinary loss of thiamine, the metabolite, and may blunt the cofactor effect. No dose change is specified (product summary).
-
Neuromuscular blocking drugs (anesthesia medicines that relax muscle, such as succinylcholine and rocuronium): Severity: caution. Thiamine may increase their effect. Telling the anesthesia team is the mitigation.
-
Antacids and binding resins (calcium carbonate, colestipol, cholestyramine): Severity: caution. Taken together they can lower absorption of an oral dose and reduce effect. The labeled gap is at least 2 hours (Vidal monograph).
-
Macrogol laxatives (polyethylene glycol, an over-the-counter bowel prep): Severity: monitor. They can lower absorption of a dose taken at the same time. The labeled gap is at least 2 hours after the laxative (Vidal monograph).
-
Cholinergic supplements (alpha-GPC, a choline donor; huperzine A): Severity: theoretical caution. Animal work shows higher choline uptake, so stacking could add headache or agitation. No human study exists.
Populations who should avoid Sulbutiamine:
- Hypersensitivity to sulbutiamine or to an excipient (an inactive ingredient), including sunset yellow E110 (a yellow food dye) in Arcalion tablets: absolute contraindication, because of rash or allergy.
- Breastfeeding: the label says not to use it, because milk transfer is unknown and a risk to the infant is not excluded.
- Pregnancy, any trimester: human data are limited (the label cites fewer than 300 pregnancies); animal studies showed no teratogenicity (no birth-defect signal). The label prefers avoidance.
- Age under 18 years: the Arcalion label states that safety and efficacy are not established and that the product is not for that age group.
- Hereditary sugar-absorption disorders (galactose or fructose intolerance, or sucrase-isomaltase deficiency, an inability to break down table sugar): Arcalion tablets contain lactose, glucose, and sucrose, so the label discourages use.
Risk Mitigation Strategies
-
Morning and midday dosing: The label splits the oral dose across the morning and midday meals, which keeps it away from sleep and lowers the chance of agitation or tremor.
-
Four-week cap unless reassessed: The labeled course is capped at four weeks, which limits how long agitation, tremor, and other labeled effects can accumulate.
-
Separate binders by two hours: Antacids, binding resins, and macrogol laxatives can cut absorption. A two-hour gap is the labeled mitigation for a weaker effect.
-
Named before anesthesia: Thiamine may deepen neuromuscular block. Telling the anesthesia team is the mitigation for a stronger muscle relaxant effect.
-
Rash stops that formulation: Uncommon rash, and allergy to sunset yellow in some tablets, is the signal to stop that formulation.
-
Not a replacement for psychiatric care: In the published bipolar case, rising unsupervised use coincided with missed visits. Continuing scheduled care is the mitigation for that disruption.
Therapeutic Protocol
-
Labeled oral dose: The Arcalion summary uses 400–600 mg a day in adults, as two or three 200 mg doses, administered orally with water. That is the pharmaceutical pattern, not a longevity protocol.
-
Split dosing and clock time: Doses are split between the morning meal and the midday meal. The half-life is about 5 hours, so a single late dose is not the labeled pattern.
-
Course length: The label caps the course at four weeks for physical or mental inhibition with low activity. It is not presented as lifelong.
-
Competing vitamin B1 approach: Benfotiamine is the other synthetic vitamin B1 derivative in wide use. In mice it raised blood and liver thiamine but not brain thiamine, unlike the disulfide class. Neither is framed here as the default.
-
Who popularized the fatigue use: Servier popularized Arcalion in France for asthenia. Egis markets Enerion for the same symptomatic use. No longevity clinic protocol was identified.
-
Genetic variants: No polymorphism (a common gene spelling difference), including vitamin B1 transporters, has a published dose rule for sulbutiamine.
-
Sex: The day-7 fatigue signal at 600 mg was seen in women only and did not last to day 28. No sex-specific dose is established.
-
Age: The label reserves the 400–600 mg pattern for adults 18 and older, with no separate older-adult dose. The bedwetting trial’s 100 mg in children is not the labeled pattern.
-
Baseline vitamin B1: No trial set the dose from a baseline thiamine diphosphate level. A low store is a reason the cofactor rationale is more plausible, not a numeric dose chart.
-
Existing illness: The label’s indication is inhibition with low activity, and it states that a true depressive episode still needs an antidepressant. Studied add-on settings include clomipramine and donepezil.
Discontinuation & Cycling
-
Course versus lifelong use: The labeled use is a course of at most four weeks, not continuous longevity use. Sulbutiamine is a single compound, so there is no second agent to stop on a different day.
-
Withdrawal: No withdrawal syndrome is described in the product summary or in the trials reviewed here.
-
Taper: No taper is specified. Overdose symptoms on the label are described as transient, and routine stopping is not given a step-down schedule.
-
Cycling: Cycling to preserve an effect is not established. Trials do not show loss of effect that a cycle would fix. One bipolar case described escalating use, which is misuse rather than a recommended cycle.
Sourcing and Quality
-
Medicine versus supplement: Arcalion (Servier) and Enerion (Egis) are medicines in some countries. In the United States it is not an approved drug. An April 2025 Food and Drug Administration (FDA) letter says it is not a dietary ingredient. Trials used the medicine.
-
Label contents: The compound name sulbutiamine, not benfotiamine or fursultiamine (other vitamin B1 derivatives), and a milligram amount per dose. A blend that hides the milligrams does not match the 200 mg dose used in the trials.
-
Third-party testing: For supplements, a United States Pharmacopeia (USP) or NSF International certificate is the practical purity check. No brand ranking was found.
-
Excipients in Arcalion: The coated tablet contains lactose, glucose, sucrose, and sunset yellow (E110). People with sugar-absorption disorders or dye allergy need a formulation without those excipients.
-
Studied brands: Arcalion 200 mg and Enerion are the products named in the clinical papers. Matching that dose is more informative than matching a brand slogan.
Practical Considerations
-
Time to effect: A fatigue signal has been described at about one week and, in an open series, at about two months. The placebo-controlled fatigue trial showed no difference at 28 days. Functional scores in depression differed by four weeks.
-
Common pitfalls: Treating animal memory findings as a healthy-adult result, confusing sulbutiamine with benfotiamine, expecting the day-7 fatigue signal to last, and taking the dose late in the day.
-
Regulatory status: Arcalion is a French medicine for low drive, capped at four weeks. An April 2025 FDA letter says it is not a dietary ingredient. Calling it one misbrands the product. A metabolite can mimic boldenone (an anabolic steroid) on a doping screen.
-
Access: It is not a high-cost specialty drug. In France, Arcalion is a medicine sold without a required prescription. Elsewhere, access follows local medicine or supplement rules.
Interaction with Foundational Habits
-
Sleep: Direction: possible blunting if the dose is late. The label lists uncommon agitation and tremor, and extreme animal doses changed the sleep-wake pattern. Practical point: morning and midday dosing, not an evening dose.
-
Nutrition: Direction: indirect. Sulbutiamine is a vitamin B1 prodrug and does not replace food sources of vitamin B1 or other nutrients. No depletion of a second nutrient is established. The label takes it with the morning and midday meals, with water.
-
Exercise: Direction: none shown for performance or muscle gain. Athletes have used it, and a metabolite can mimic a boldenone marker in urine tests. No trial shows a blunting or boosting of training adaptations.
-
Stress management: Direction: indirect. In one depression trial, day-to-day functioning improved sooner without a change in the depression score itself. It is not a stress treatment. Animal work shows cortical dopamine and glutamate receptor changes, which are not a human stress result.
Monitoring Protocol & Defining Success
Before a first course, a morning thiamine diphosphate level, seated blood pressure, and a 0–10 drive or fatigue rating document the start. The product summary does not require a liver or kidney panel. People on diuretics, who may already lose thiamine in urine, are the group in whom that vitamin result changes the reading. A pregnancy test matters when pregnancy is possible, because the label prefers avoidance.
Repeat the same measures at 1 week and at 4 weeks, the labeled maximum course. There is no studied schedule for multi-month longevity use. If use continues, the same checks every 3 months are the practical cadence, sooner if agitation, rash, tremor, or insomnia appears.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Thiamine diphosphate (whole blood or red cells) | No sulbutiamine-specific target; track change from the person’s own baseline | Shows whether vitamin B1 cofactor stores were low at the start | Morning sample. Laboratory reference intervals differ. Serum thiamine alone is a weaker store marker. |
| Seated blood pressure | Under 120/80 mmHg | Agitation and malaise can travel with a higher pressure | Morning, before the dose, seated. Units are millimeters of mercury. A common diagnostic threshold is 130/80 or above. |
| Resting heart rate | No sulbutiamine-specific target; track change from the person’s own baseline | Tremor and agitation may show up as a faster resting rate | Same time of day, before the dose. Many adults sit near 60–80 beats per minute. |
| Drive or fatigue rating (0–10) | No established target; a better score than the person’s own baseline | The studied outcome is how the person functions, not a blood test | Same time of day. Weekly during a four-week course. |
Qualitative markers:
- Sleep onset and nighttime waking
- Agitation, tremor, or headache
- Nausea, stomach pain, or loose stools
- Daytime drive and mental stamina
- Rash or other skin change
Emerging Research
-
Childhood bedwetting trial: NCT06497647 compares sulbutiamine, imipramine, and both in about 450 children, with wet nights as the main endpoint; registry status is unknown. A 2026 report from that question found more complete dryness with sulbutiamine than with imipramine (Ahmed Mahmoud et al.). It does not test adult longevity.
-
Adult fatigue replication: No recruiting adult trial of sulbutiamine for fatigue, thinking, or lifespan was found on ClinicalTrials.gov in this search. A repeat of the post-infectious fatigue design, with the one-month result as the main endpoint, could weaken or support that claim (Tiev et al.).
-
Brain delivery versus benfotiamine: Oral benfotiamine raised mouse blood and liver thiamine but not brain thiamine, unlike disulfide derivatives such as sulbutiamine (Volvert et al.). A human comparison of thinking or fatigue could strengthen or undercut a brain-targeted rationale. That comparison is not published.
Conclusion
Sulbutiamine is a fat-soluble made form of vitamin B1. It is sold as a medicine for low drive and tiredness in some countries, and as a dietary supplement in others. For a longevity-oriented adult, the evidence is narrow. Human studies enrolled people with tiredness after infection, slowing during low mood, early memory disease, or nerve injury from diabetes. They did not enroll healthy adults seeking a longer healthy life. The large placebo comparison in tiredness after infection did not show a benefit that lasted to the end of the course. A depression trial found better day-to-day functioning without a stronger effect on the mood score itself. A trial in early memory disease suggested a benefit only when those drugs were given in one order.
Uncommon effects on the product label include agitation, headache, tremor, nausea, and rash. Massive intake is described as brief agitation and tremor. One case linked rising unsupervised use with disrupted care in bipolar disorder. The label caps the medicine course at four weeks, prefers avoidance in pregnancy, and says not to use it while breastfeeding or under 18 years. Much of the favorable tiredness writing had no comparison group. One large series was described by its authors as commercial, and the branded medicines are sold by companies that gain if they are used. The brain-entry story is plausible and is better supported in animals than in healthy people. The evidence base is too thin to read sulbutiamine as an established longevity intervention.